Idiopathic Pulmonary Fibrosis clinical trials at UCSF

6 in progress, 3 open to eligible people

Showing trials for

  • Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

    open to eligible people ages 40 years and up

    ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.

    San Francisco, California and other locations

  • Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

    open to eligible people ages 40 years and up

    Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.

    San Francisco, California and other locations

  • Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

    open to eligible people ages 40-85

    The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.

    San Francisco, California and other locations

  • Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

    Sorry, not yet accepting patients

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

    San Francisco, California and other locations

  • Leramistat in Patients With IPF

    Sorry, not currently recruiting here

    To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).

    Fresno, California and other locations

  • Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    Sorry, in progress, not accepting new patients

    This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). There is a 48-week randomized treatment phase followed by an optional, open-label extension phase.

    San Francisco, California and other locations

Our lead scientists for Idiopathic Pulmonary Fibrosis research studies include .

Last updated: